{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03639935","nct_id":"NCT03639935","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03639935. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Rucaparib 600 mg PO BID days 1-28 Nivolumab 240 mg IV days 1 and 15","label":"Rucaparib and Nivolumab","type":"EXPERIMENTAL"}],"collaborators":["Dana-Farber Cancer Institute","Vanderbilt University Medical Center"],"completion_date":{"date":"2024-04-30","type":"ACTUAL"},"conditions":["Biliary Tract Cancer"],"enrollment":{"count":32,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Rucaparib","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"}],"last_update":"2025-06-03","lead_sponsor":"University of Michigan Rogel Cancer Center","official_title":"Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-02-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Proportion of Patients Alive and Without Radiological or Clinical Progression at 4 Months","timeFrame":"4 months"}],"references":[{"citation":"Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V. A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02. Clin Cancer Res. 2026 Jul 23. doi: 10.1158/1078-0432.CCR-25-1114. Online ahead of print.","pmid":"42489677","type":"DERIVED"}],"start_date":{"date":"2019-03-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy","url":"https://clinicaltrials.gov/study/NCT03639935"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03639935"}